The Jie Tai Si sugar chain detection kit developed by Jiangsu SysDiagno Biotech, based in the Taizhou Medical High-tech Zone, was rated as an innovation achievement and included in the 2024 Medical Device Registration Work Report of the National Medical Products Administration.
The report is seen as a barometer of China's medical devices field and the selection underscores the product's advantages in technological innovation, clinical value and market potential.
The sugar chain, also known as the "third life chain" beyond nucleic acids and proteins, is closely related to human health and the occurrence and development of diseases.
The product is used for early detection of liver cancer and has advantages such as easy operation, high accuracy and the ability to detect in large quantities.
Its liver cancer detection sensitivity can reach 88.54 percent and specificity reaches 95.21 percent, both of which have reached the leading international level.
Focusing on major fields of tumor diagnosis and physiological health, SysDiagno Biotech will continue to explore the application of sugar chain detection in more disease fields such as cancers and neurodegenerative diseases, said Chen Cuiying, founder and chairman of the company.
The Jie Tai Si sugar chain detection kit from SysDiagno Biotech. [Photo/WeChat account: weigg6666]